➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Mallinckrodt
Dow
Moodys
Colorcon

Last Updated: June 5, 2020

DrugPatentWatch Database Preview

Patent: 10,144,772

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,144,772
Title:Method for treating melanoma
Abstract: The present invention relates to a TNF.alpha. blocking agent for use in the treatment and prevention of melanoma in a subject in whom melanoma cells express MHCI and in whom stroma cells exhibit TNF expression.
Inventor(s): Segui; Bruno (Toulouse, FR), Andrieu-Abadie; Nathalie (Toulouse, FR), Levade; Thierry (Toulouse, FR), Colacios Viatge; Celine (Toulouse, FR), Rochaix; Philippe (Toulouse, FR), Bertrand; Florie (Toulouse, FR), Benoist; Herve (Toulouse, FR), Rochotte; Julia (Toulouse, FR)
Assignee: INSERM (Institut National de la Sante et de la Recherche Medicale) (Paris, FR) Centre Hospitalier Universitaire de Toulouse (Toulouse, FR) Institut Claudius Regaud (Toulouse, FR) Universite Paul Sabatier Toulouse III (Toulouse, FR)
Application Number:15/310,158
Patent Claims:see list of patent claims

Details for Patent 10,144,772

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Centocor Inc REMICADE infliximab VIAL 103772 001 1998-08-24   Start Trial INSERM (Institut National de la Sante et de la Recherche Medicale) (Paris, FR) Centre Hospitalier Universitaire de Toulouse (Toulouse, FR) Institut Claudius Regaud (Toulouse, FR) Universite Paul Sabatier Toulouse III (Toulouse, FR) 2034-05-12 RX Orphan search
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02   Start Trial INSERM (Institut National de la Sante et de la Recherche Medicale) (Paris, FR) Centre Hospitalier Universitaire de Toulouse (Toulouse, FR) Institut Claudius Regaud (Toulouse, FR) Universite Paul Sabatier Toulouse III (Toulouse, FR) 2034-05-12 RX Orphan search
Immunex ENBREL etanercept SYRINGE 103795 002 1998-11-02   Start Trial INSERM (Institut National de la Sante et de la Recherche Medicale) (Paris, FR) Centre Hospitalier Universitaire de Toulouse (Toulouse, FR) Institut Claudius Regaud (Toulouse, FR) Universite Paul Sabatier Toulouse III (Toulouse, FR) 2034-05-12 RX Orphan search
Abbvie Inc HUMIRA adalimumab SYRINGE 125057 001 2002-12-31   Start Trial INSERM (Institut National de la Sante et de la Recherche Medicale) (Paris, FR) Centre Hospitalier Universitaire de Toulouse (Toulouse, FR) Institut Claudius Regaud (Toulouse, FR) Universite Paul Sabatier Toulouse III (Toulouse, FR) 2034-05-12 RX search
Abbvie Inc HUMIRA adalimumab VIAL 125057 002 2002-12-31   Start Trial INSERM (Institut National de la Sante et de la Recherche Medicale) (Paris, FR) Centre Hospitalier Universitaire de Toulouse (Toulouse, FR) Institut Claudius Regaud (Toulouse, FR) Universite Paul Sabatier Toulouse III (Toulouse, FR) 2034-05-12 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Merck
McKesson
Medtronic
Colorcon
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.